CX11 / Vincentage Pharmaceutical, CORXEL - LARVOL DELTA

VICTOR-HTN: A Study of VCT220 in Participants With Hypertension and Obesity or Overweight (clinicaltrials.gov) - P2 | N=160 | Active, not recruiting | Sponsor: Vincentage Pharma Co., Ltd | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Genetic Disorders • Hypertension • Obesity

A Food-Effect Study of CX11 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Vincentage Pharma Co., Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

VCT220-III-01: A Research Study of VCT220 in Adult Chinese Participants With Obesity (clinicaltrials.gov) - P3 | N=840 | Completed | Sponsor: Vincentage Pharma Co., Ltd | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: Corxel Pharmaceuticals | Trial completion date: Jan 2027 ➔ Apr 2027 | Trial primary completion date: Dec 2026 ➔ Apr 2027

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial. (PubMed, Signal Transduct Target Ther) - P2 | "VCT220, a once-daily oral nonpeptide GLP-1RA, produced rapid and clinically meaningful weight loss with metabolic benefits over 16 weeks, showing a tolerability profile consistent with the class. These findings support further global phase III evaluation to further verify the efficacy and safety of VCT220 as well as potential cardiometabolic benefits."

Clinical • Journal • P2 data • Genetic Disorders • Obesity

Corxel Pharmaceuticals…announced positive top-line results from its Phase 2 trial evaluating CX11, an oral small molecule GLP-1 receptor agonist (GLP-1 RA), in obese and overweight participants in the United States (GlobeNewswire) - "...U.S. Phase 2 trial met primary endpoints....CORXEL plans to advance into pivotal global Phase 3 studies of CX11 in weight management.....The Phase 2 trial (NCT07011797) enrolled 246 adults with obesity (BMI ≥30 kg/m²) or who were overweight (27 kg/m² ≤ BMI <30 kg/m²) with at least one weight-related comorbidity in the United States....At 36 weeks, CX11 achieved up to 11.5% weight loss among U.S. obesity patients, with weight loss continuing at a consistent rate and no evidence of a slowing trajectory. Throughout the 36-week double-blind treatment period, CX11 demonstrated a favorable gastrointestinal (GI) tolerability and safety profile."

New P3 trial • P2 data • Obesity

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Corxel Pharmaceuticals

New P1 trial • Genetic Disorders • Obesity

CX11202: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus (clinicaltrialsregister.eu) - P1/2 | N=121 | Recruiting | Sponsor: Corxel Pharmaceuticals Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants (clinicaltrials.gov) - P2 | N=250 | Completed | Sponsor: Corxel Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

Vincentage Pharma Reports Positive Top-Line Results from Pivotal Phase 3 Trial of VCT220 in Obese or Overweight Chinese Adults (The Manila Times) - "The Phase 3 trial (NCT06939296) enrolled 840 adults with obesity (BMI ≥28 kg/m²) or overweight (24 kg/m² ≤ BMI At 52 weeks, VCT220 achieved mean body weight reduction of -12.2% and -12.4% in the 120 mg and 160 mg groups, respectively, both significantly greater than -1.3% for placebo. Across the 52-week double-blind treatment period, VCT220 demonstrated favorable overall tolerability, with a safety profile consistent with existing GLP-1 therapeutics."

P3 data: top line • Obesity

CX11202: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus (clinicaltrialsregister.eu) - P1/2 | N=121 | Not yet recruiting | Sponsor: Corxel Pharmaceuticals Inc.

New P1/2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: Corxel Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Vincentage Pharma Co., Ltd | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Vincentage Pharma Co., Ltd | Active, not recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Aug 2025 | Trial primary completion date: Oct 2025 ➔ Jul 2025

Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Food-Effect Study of CX11 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Vincentage Pharma Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Vincentage Pharma Co., Ltd | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity • Renal Disease

A Food-Effect Study of CX11 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Vincentage Pharma Co., Ltd

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist (GlobeNewswire) - "Proceeds from the financing will be used to: Advance the lead program, CX11, through its ongoing U.S. Phase 2 trial to treat obesity and overweight patients, its planned global Phase 2 trial to treat Type 2 Diabetes Mellitus (T2DM) and initial preparations for CX11’s Phase 3 trials; Advance the company’s additional programs through clinical development; and Further strengthen the company’s global operational and development capabilities to support global multiregional clinical programs."

Financing • Obesity • Type 2 Diabetes Mellitus

A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Vincentage Pharma Co., Ltd

New P1 trial • Genetic Disorders • Obesity • Renal Disease

VICTOR-HTN: A Study of VCT220 in Participants With Hypertension and Obesity or Overweight (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: Vincentage Pharma Co., Ltd

New P2 trial • Cardiovascular • Genetic Disorders • Hypertension • Obesity

A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P2 | N=240 | Not yet recruiting | Sponsor: Corxel Pharmaceuticals

New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single Ascending Doses of VCT220 Tablets in Chinese Healthy Subjects, and the Effect of Food on its Pharmacokinetic Profile (ChiCTR) - P1 | N=72 | Completed | Sponsor: West China Second University Hospital of Sichuan University; West China Second University Hospital of Sichuan University (WCSUH- SCU)

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Vincentage Pharma Co., Ltd | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Vincentage Pharma Co., Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Vincentage Pharma Co., Ltd | Not yet recruiting ➔ Completed

Trial completion • Genetic Disorders • Hepatology • Liver Failure • Obesity